logo-loader
NASDAQ:MDGL

Madrigal Pharmaceuticals Inc

Receive alerts
Market:
NASDAQ
Price
397.05 USD
Day Change
-0.26%
Market Cap:
$9.21 b
52 weeks high
614.29
52 weeks low
354.12

In brief

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) is a clinical-stage biopharmaceutical company developing treatments that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The company’s lead candidate, MGL-3196, is an orally administered, liver-directed, thyroid hormone receptor (THR) β-selective agonist in clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and familial dyslipidemias/hypercholesterolemias, among other related indications.